In last trading session, Tango Therapeutics Inc (NASDAQ:TNGX) saw 0.52 million shares changing hands with its beta currently measuring 1.00. Company’s recent per share price level of $1.46 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $157.84M. That closing price of TNGX’s stock is at a discount of -723.29% from its 52-week high price of $12.02 and is indicating a premium of 23.97% from its 52-week low price of $1.11. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.53 million shares which gives us an average trading volume of 720.86K if we extend that period to 3-months.
For Tango Therapeutics Inc (TNGX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.35 in the current quarter.
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
Tango Therapeutics Inc’s shares saw a change of -52.75% in year-to-date performance and have moved 13.18% in past 5-day. Tango Therapeutics Inc (NASDAQ:TNGX) showed a performance of -5.19% in past 30-days. Number of shares sold short was 10.04 million shares which calculate 10.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 13 to the stock, which implies a rise of 88.77% to its current value. Analysts have been projecting 13 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would drop -790.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -790.41% for stock’s current value.
Tango Therapeutics Inc (TNGX) estimates and forecasts
This year revenue growth is estimated to fall -30.84% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.73M for the same. And 6 analysts are in estimates of company making revenue of 6.36M in the next quarter. Company posted 6.47M and 19.88M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 7.47% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -17.02% while estimates for its earnings growth in next 5 years are of -10.41%.
Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders
Insiders are in possession of 8.40% of company’s total shares while institution are holding 99.50 percent of that, with stock having share float percentage of 108.62%. Investors also watch the number of corporate investors in a company very closely, which is 99.50% institutions for Tango Therapeutics Inc that are currently holding shares of the company. TRV GP IV, LLC is the top institutional holder at TNGX for having 19.2 million shares of worth $164.75 million. And as of 2024-06-30, it was holding 17.7276 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 13.33 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.3075 of outstanding shares, having a total worth of $114.38 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Small-Cap Value Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.2 shares of worth $3.22 million or 2.04% of the total outstanding shares. The later fund manager was in possession of 1.66 shares on Dec 31, 2024 , making its stake of worth around $2.43 million in the company or a holder of 1.54% of company’s stock.
